Eli Lilly: Q4 above estimates

(CercleFinance.com) - Unveiled before Wall Street opens on Wednesday, Eli Lilly's Q4 results revealed a loss of 1.
58 dollar per share, against EPS of 73 cents a year earlier.

However, on an adjusted basis, the US pharmaceutical giant generated EPS of 1.14 dollar, 7 cents above the consensus.

Meanwhile, revenues increased by more than expected to 6.16 billion dollars, after 5.76 billion dollars in Q4 2016 and 5.94 billion dollars expected by the consensus.

Eli Lilly targets adjusted EPS of 4.81 dollars to 4.91 dollars, with FY revenues of 23 billion to 23.5 billion dollars. Meanwhile, the market is respectively looking for 4.65 dollars and 23.21 billion dollars.


Copyright (c) 2018 CercleFinance.com. All rights reserved.